[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557822":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":18,"responsibleParty":35,"collaborators":7,"id":38,"slug":7,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":7,"eligibilityCriteria":42,"healthyVolunteers":39,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Hunan Cancer Hospital","OTHER",null,[9],{"type":10,"name":11,"description":11,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","The clinical value of 18F-FAPI-04 PET\u002FCT and PET\u002FMR imaging in the diagnosis and staging of gastric cancer",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Hui Ye","CONTACT","86-13755117105","yuxin75831@163.com",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Hunan Cancer hospital","RECRUITING","Changsha","Hunan","410000","China","CN",{"type":28,"coordinates":29},"Point",[30,31],112.97087,28.19874,{"lat":31,"lon":30},[34],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},{"type":36,"investigatorFullName":14,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Professor","100557822",false,"NCT06543108","Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET\u002FCT and PET\u002FMR in Gastric Cancer","Inclusion Criteria:\n\n1. Age over 18 years old;\n2. Diagnosed as a patient with gastric cancer;\n3. Receive FAPI PET\u002FCT and FDG PET\u002FCT imaging within one week;\n4. Perform serum tumor marker testing one week before and after scanning\n\nExclusion Criteria:\n\n1. History of other malignant tumors;\n2. Patients with severe infections, severe underlying diseases such as heart, kidney, and liver;\n3. Patients with contraindications for PET-CT examination, poor physical condition, and inability to tolerate the examination;\n4. Patients with unorganized pathology or incomplete clinical data","ALL","18 Years","90 Years",{"count":47,"type":48},30,"ESTIMATED","OBSERVATIONAL","This project aims to comprehensively analyze the diagnostic efficacy of SUVmax, SUVean, TLG, MTV, etc. in gastric cancer through 18F-FAPI-04 PET\u002FCT imaging combined with serum tumor markers and other methods, and construct a molecular imaging diagnostic model for gastric cancer; Next, analyze the diagnostic efficacy of 18F-FAPI-04 PET\u002FCT and PET\u002FMR multimodal imaging in evaluating SUVmax, PET\u002FCT-PCI, and PET\u002FMR-PCI for gastric cancer peritoneal metastasis, and construct a molecular imaging diagnostic model for gastric cancer peritoneal metastasis; Exploring the clinical value of 18F-FAPI-04 PET\u002FCT and PET\u002FMR imaging in the diagnosis and staging of gastric cancer.",[52],"Gastric Cancer","2024-08-03",{"date":55,"type":56},"2024-08-07","ACTUAL",{"date":58,"type":56},"2024-01-01",{"date":60,"type":48},"2028-12-31",{"name":5,"class":6},1]